TABLE 1.
Prevalence of IgM and IgG antibodies to SARS‐CoV‐2 AMong cancer patients with COVID‐19 and other hospitalized COVID‐19 patients
| Prevalence % (95% confidence interval) | P value | ||
|---|---|---|---|
| Cancer patients (n = 40) | COVID‐19 Patients (n = 1430) | ||
| Prevalence IgG | |||
| All | 72.5 (58.0‐87.0) | 90.3 (88.7‐91.8) | <.001 |
| Age group (years) | |||
| ≤70 | 67.7 (50.3‐85.2) | 91.2 (89.6‐92.9) | <.001 |
| >70 | 88.9 (63.3‐100.0) | 86.4 (82.4‐90.5) | .83 |
| Sex | |||
| Female | 72.7 (52.5‐92.9) | 90.9 (88.8‐93.0) | .008 |
| Male | 72.2 (49.3‐95.1) | 89.7 (87.4‐91.9) | .026 |
| Prevalence IgM | |||
| All | 20.0 (7.0–33.0) | 31.7 (29.3‐34.1) | .12 |
| Age group (years) | |||
| ≤70 | 12.9 (0.4‐25.4) | 30.6 (27.9‐33.3) | .043 |
| >70 | 44.4 (3.9‐85.0) | 36.1 (30.4‐41.7) | .61 |
| Sex | |||
| Female | 9.1 (0.0‐22.1) | 28.1 (24.8‐31.4) | .068 |
| Male | 33.3 (9.2‐57.5) | 35.4 (31.8‐38.9) | .86 |